Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing
Authors:
- 1 May 2001
- journal article
- review article
- Published by Springer Nature in Investigational New Drugs
- Vol. 19 (2) , 171-177
Abstract
Body surface area (BSA) was introduced intomedical oncology in order to derive a safestarting dose for phase I studies ofanticancer drugs from preclinical animaltoxicology data. It is not clear...Keywords
This publication has 39 references indexed in Scilit:
- Relationships among liver and kidney volumes, lean body mass and drug clearanceBritish Journal of Clinical Pharmacology, 1998
- Stroke Volume and Cardiac Output in Normotensive Children and AdultsCirculation, 1997
- Lean body mass, body surface area and epirubicin kineticsAnti-Cancer Drugs, 1994
- Is Dose Normalization to Weight or Body Surface Area Useful in Adults?JNCI: Journal of the National Cancer Institute, 1990
- Phase I studies with carboplatin at the Royal Marsden HospitalCancer Treatment Reviews, 1985
- Disposition of Antipyrine and Phenytoin Correlated with Age and Liver Volume in ManClinical Pharmacokinetics, 1981
- Antipyrine disposition and liver size in the elderlyEuropean Journal of Clinical Pharmacology, 1978
- CLINICAL STUDIES OF THE BLOOD VOLUME. II. THE RELATION OF PLASMA AND TOTAL BLOOD VOLUME TO VENOUS PRESSURE, BLOOD VELOCITY RATE, PHYSICAL MEASUREMENTS, AGE AND SEX IN NINETY NORMAL HUMANSJournal of Clinical Investigation, 1937
- STUDIES OF KIDNEY FUNCTION IN CHILDRENJournal of Clinical Investigation, 1935
- STUDIES OF UREA EXCRETION. IIIJournal of Clinical Investigation, 1928